Corporate Vice President, Global Medical Affairs, Rare Disease

at  Novo Nordisk

Corporate Vice President, Global Medical Affairs, Rare Disease
Category: Medical Affairs
Location:Zurich, Switzerland Zurich, CH
Corporate Vice President, Global Medical Affairs, Rare Disease
Are you an esteemed and forward-thinking leader in the medical affairs arena, driven by a passion to bring about meaningful change for patients? Do you have a demonstrated history of implementing impactful medical strategies within specialty care? We are in search of an outstanding leader to guide our Global Medical Affairs function for Novo Nordisk Rare Disease. Read on and apply today.

QUALIFICATIONS

You are an accomplished global leader in medical affairs within a large pharmaceutical company or biotech, with over a decade of experience in the discipline ideally focused on specialty care.

In addition, you possess:

• A proven track record for successfully leading and developing a high-performing global medical affairs function, ideally in a similarly complex, global matrix environment.
• A proven track record for successful involvement in multiple global launch processes.
• A proven track record of positively influencing clinical practices and transforming disease treatment methodologies.
• A history of proactive and meaningful engagement with key opinion leaders (KOLs) and external medical experts, establishing a company’s presence at scientific forums and advisory boards.
• An advanced degree in a relevant field (e.g., MD, PhD, PharmD).

As an individual, you are pioneering and curious, driven by a passion to make a tangible and positive impact for patients. You have a forward-thinking perspective, coupled with a pragmatic, results-oriented approach. As an empowering and resilient leader, you motivate and bring together high-performing teams of exceptional professionals. Acknowledged as a strong collaborator and stakeholder manager, you are valued for your capacity to listen, build relationships, and collectively drive change across all levels of an organisation.

• Strategic Leadership: Set strategic direction for global medical affairs initiatives, drive the development and execution of global medical strategies for rare disease therapies, ensuring alignment with the Rare Disease strategy and a strong focus on medical excellence.
• Organisational Leadership: Lead, inspire, and develop the Global Medical Affairs team within Rare Disease. Drive performance and growth across the area, team, and broader Medical Affairs network (particularly in the regions). Drive standards and expectations for medical affairs activities in connection with launches within our therapy areas. Provide coaching and support, fostering adaptability, quality decision-making and a focus on continuous improvement.
• External Engagement and Advocacy: Foster strong, credible relationships with key opinion leaders (KOLs), International Professional Associations (IPAs) and Medical Experts, identifying scientific opportunities, ensuring proper scientific communication and strategic alignment with brand strategies. Represent the company at scientific forums, advisory boards, and medical conferences within the rare disease space. Provide medical education among Healthcare Professionals (HCPs) through scientific meetings and symposia.
• Advancing Clinical Development: Drive Real World Evidence (RWE) initiatives for Rare Disease, Medical Education strategy/plans, Medical Guidance and ensure support to rare blood and rare endocrine clinical activities and proper handling of Investigators Sponsored Studies process and grant requests.
• Cross-functional Collaboration: Collaborate with internal and external stakeholders, including product development, regulatory affairs, pharmacoeconomics, marketing and safety etc., ensuring comprehensive alignment and integration of medical affairs strategies for rare disease therapeutics.
• Contribute to Rare Disease Leadership: Actively participate and contribute as a valuable member of the Rare Disease Leadership Team, offering insights, expertise, and strategic guidance to advance the organization’s rare disease initiatives